This slowing contributes to the appetite suppression that drives weight loss and the postprandial glucose-lowering effect, and it also drives most of the gastrointestinal side effect profile.[1],[2] A 2025 review in the Journal of Clinical Endocrinology & Metabolism summarizes the published evidence: GLP-1 receptor agonists impact gastric, intestinal, and gallbladder motility simultaneously, with effects on gastric fundus relaxation, antral contractility inhibition, increased pyloric tone, and reduced small intestinal motility.[3] The path from this mechanism to constipation is straightforward
The publicity around ProRx recalls and other compounding pharmacy issues has put pressure on the entire industry to demonstrate higher quality
Support ongoing pharmacovigilance and research to clarify causality and identify higher-risk subgroups
Thuc Vinluta 1200mg c bn ti cc bnh vin vi nh thuc do chnh sch gi khc nhau
This includes Addisons disease, congenital adrenal hyperplasia, and adrenogenital syndrome